Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
19 Mai 2023 - 02:38PM
Stereotaxis (NYSE: STXS) today announced a global collaboration
with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System
with Stereotaxis’ Robotic Magnetic Navigation systems.
The combination of Abbott’s leading cardiac
mapping system with Stereotaxis’ advanced robotic technology brings
together highly detailed real-time diagnostic information with the
unprecedented precision and stability of robotics during therapy
delivery. Technology integration enhances the physician experience,
streamlines procedural workflow, and supports the improved
treatment of patients with abnormal heart rhythms. Stereotaxis and
Abbott have successfully completed integration of their
technologies and performed testing demonstrating joint
compatibility. The integrated technologies are cleared for use in
Europe with additional regulatory clearances expected in the coming
months.
"The combination of these two technologies is a
seminal event for the community of physicians who have pioneered
and championed robotics in electrophysiology,” said Dr. J. Peter
Weiss, electrophysiologist and clinical professor of medicine at
Banner University of Arizona Medical Center. “Joint use of EnSite X
with Robotic Magnetic Navigation is beneficial for the broad
spectrum of cardiac ablation procedures and is most impactful in
treating complex and challenging cardiac arrhythmias.”
Millions of individuals worldwide suffer from
arrhythmias – abnormal heart rhythms that result when the heart
beats too quickly, too slowly, or with an irregular pattern. Left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest. Abbott's EnSite X
System is the latest innovation available in cardiac mapping and
received US FDA clearance in 2021. Robotic Magnetic Navigation
introduces the benefits of robotic precision, stability and safety
to cardiac ablation procedures using advanced computer-controlled
magnetic fields for direct control of a catheter tip.
“Stereotaxis is delighted to collaborate with
Abbott and to be able to share this significant milestone for the
electrophysiology field,” said David Fischel, Chairman and CEO of
Stereotaxis. “This collaboration further reinforces our commitment
to meaningful innovations that advance the frontiers of medical
progress. It provides additional choice for the community of
robotic users and ensures patients, physicians and providers can
benefit from the combination of the finest diagnostic and
therapeutic technologies.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024